Startups
Lighthouse Pharma is a clinical stage private biopharmaceutical company pioneering precision medicine approaches to major unmet medical needs. Lighthouse’s lead program, LHP588, is in Phase 2 clinical for P. gingivalis-positive Alzheimer's disease.
Overview
Total raised
$12M
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 28, 2026 | Lighthouse Pharmaceuticals: $12 Million Raised For Targeting Alzheimer’s Disease | Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company developing small-molecule therapies for neurodegenerative and inflammatory diseases, has closed a $12 million Series A financing round led by Double Point Ventures, with... |
| Apr 28, 2026 | Lighthouse Pharmaceuticals Raises $12M in Series A Funding | Lighthouse Pharmaceuticals, a Novato, CA-based clinical-stage biopharmaceutical company developing therapies for neurodegenerative and inflammatory diseases, raised $12M in Series A funding. The round was led by Double Point Ventures, with ... |
| Lighthouse Pharma | “Lighthouse Pharma is a clinical stage private biopharmaceutical company pioneering precision medicine approaches to major unmet medical needs. Lighthouse’s lead program, LHP588, is in Phase 2 clinical for P. gingivalis-positive Alzheimer's... |
Reviews 0
FAQ about Lighthouse Pharma
How much funding has Lighthouse Pharma raised?
Lighthouse Pharma has raised $12M in total across 1 funding round.
What has the press written about Lighthouse Pharma?
Parsers VC has collected 4 articles mentioning Lighthouse Pharma, among them “Lighthouse Pharmaceuticals: $12 Million Raised For Targeting Alzheimer’s Disease” (Apr 28, 2026) and “Lighthouse Pharmaceuticals Raises $12M in Series A Funding” (Apr 28, 2026).
Is Lighthouse Pharma still active?
Yes, Lighthouse Pharma is active; its latest activity on Parsers VC dates from Oct 10, 2026.